Immunotherapy extends survival in mouse model of hard-to-treat breast cancer (video)

Today, scientists report a new immunotherapy that extends the survival of mice that have triple negative breast tumors, a difficult-to-treat form of cancer. The researchers will present their results at the American Chemical Society Fall 2020 Virtual Meeting & Expo.

Read more

HDAC6 Can Control Tumor Growth and Halt Metastasis in Triple-Negative Breast Cancer

Genetic modifier HDAC6 was found to control tumor growth and halt metastasis in triple-negative breast cancer in vivo, according to a new study published in the journal Cancer Research by investigators at the GW Cancer Center.

Read more

Radiation/immunotherapy combo shows promise for recurrent/metastatic head and neck cancers

A new phase II trial finds that a combination of radiation therapy and immunotherapy led to encouraging survival outcomes and acceptable toxicity for patients with locally advanced head and neck squamous cell carcinoma (HNSCC). The combination of radiation and pembrolizumab may offer a new treatment option for patients who are ineligible for cisplatin chemotherapy, part of standard treatment for the disease. Findings will be presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium.

Read more

New discovery may drive the development of better, more effective immunotherapies for the treatment of breast cancer

New cancer immunotherapy approaches are revolutionizing treatment options for breast cancer patients. However, many lead to insufficient immune responses rendering the therapies incapable of completely eradicating tumors.

In a new study, published today in Science Immunology, University of California, Irvine researchers determined the molecular features of certain cells associated with breast cancer, which may open up new avenues into improving cancer immunotherapy.

Read more

Human Immune Monitoring Center at Mount Sinai to analyze the effectiveness of a novel cancer therapy drug

The Human Immune Monitoring Center (HIMC) at the Icahn School of Medicine at Mount Sinai will apply cutting-edge high-throughput technologies to evaluate the therapeutic effects of Libtayo® (cemiplimab-rwlc), a PD-1 antibody blockade developed by biotechnology company Regeneron Pharmaceuticals, Inc and Sanofi.

Read more